Advertisement
Review Article| Volume 107, ISSUE 2, P285-298, March 2023

Download started.

Ok

Updates in Cardiovascular Disease Prevention, Diagnosis, and Treatment in Women

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Medical Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Bibbins-Domingo K.
        • Grossman D.C.
        • et al.
        • Force USPST
        Statin use for the primary prevention of cardiovascular disease in adults: US preventive services task force recommendation statement.
        JAMA. 2016; 316: 1997-2007
        • Association A.H.
        Life's Essential 8.
        (Available at:)
        • Guasch-Ferre M.
        • Willett W.C.
        The Mediterranean diet and health: a comprehensive overview.
        J Intern Med. 2021; 290: 549-566
        • Hales C.M.C.M.
        • Fryar C.D.
        • Ogden C.L.
        Prevalence of obesity among adults and youth: United States, 2015-2016.
        National Center for Health Statistics. 2017; 288: 1-7
        • Garcia M.
        • Mulvagh S.L.
        • Merz C.N.
        • et al.
        Cardiovascular disease in women: clinical perspectives.
        Circ Res. 2016; 118: 1273-1293
        • van Veldhuisen S.L.
        • Gorter T.M.
        • van Woerden G.
        • et al.
        Bariatric surgery and cardiovascular disease: a systematic review and meta-analysis.
        Eur Heart J. 2022; 43: 1955-1969
        • Apovian C.M.
        • Aronne L.J.
        • Bessesen D.H.
        • et al.
        Pharmacological management of obesity: an endocrine society clinical practice guideline.
        J Clin Endocrinol Metab. 2015; 100: 342-362
        • Wilding J.P.H.
        • Batterham R.L.
        • Calanna S.
        • et al.
        Once-weekly semaglutide in adults with overweight or obesity.
        N Engl J Med. 2021; 384: 989-1002
        • Jastreboff A.M.
        • Aronne L.J.
        • Ahmad N.N.
        • et al.
        Tirzepatide once weekly for the treatment of obesity.
        N Engl J Med. 2022; 387: 205-216
        • Wilding J.P.H.
        • Batterham R.L.
        • Davies M.
        • et al.
        Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension.
        Diabetes Obes Metab. 2022; 24: 1553-1564
        • Stanford F.C.
        Controversial issues: A practical guide to the use of weight loss medications after bariatric surgery for weight regain or inadequate weight loss.
        Surg Obes Relat Dis. 2019; 15: 128-132
        • Stone N.J.
        • Robinson J.G.
        • Lichtenstein A.H.
        • et al.
        2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
        J Am Coll Cardiol. 2014; 63: 2889-2934
        • Grundy S.M.
        • Stone N.J.
        • Bailey A.L.
        • et al.
        2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
        J Am Coll Cardiol. 2018; https://doi.org/10.1016/j.jacc.2018.11.003
        • Greenland P.
        • Alpert J.S.
        • Beller G.A.
        • et al.
        2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.
        J Am Coll Cardiol. 2010; 56: e50-e103
        • Hecht H.S.
        • Cronin P.
        • Blaha M.J.
        • et al.
        2016 SCCT/STR guidelines for coronary artery calcium scoring of noncontrast noncardiac chest CT scans: A report of the Society of Cardiovascular Computed Tomography and Society of Thoracic Radiology.
        J Cardiovasc Comput Tomogr. 2017; 11: 74-84
        • Margolies L.
        • Salvatore M.
        • Hecht H.S.
        • et al.
        Digital mammography and screening for coronary artery disease.
        JACC Cardiovasc Imaging. 2016; 9: 350-360
        • Budoff M.J.
        • Achenbach S.
        • Blumenthal R.S.
        • et al.
        Assessment of coronary artery disease by cardiac computed tomography: a scientific statement from the American Heart Association Committee on Cardiovascular Imaging and Intervention, Council on Cardiovascular Radiology and Intervention, and Committee on Cardiac Imaging, Council on Clinical Cardiology.
        Circulation. 2006; 114: 1761-1791
        • Miedema M.D.
        • Duprez D.A.
        • Misialek J.R.
        • et al.
        Use of coronary artery calcium testing to guide aspirin utilization for primary prevention: estimates from the multi-ethnic study of atherosclerosis.
        Circ Cardiovasc Qual Outcomes. 2014; 7: 453-460
        • Bukkapatnam R.N.
        • Gabler N.B.
        • Lewis W.R.
        Statins for primary prevention of cardiovascular mortality in women: a systematic review and meta-analysis.
        Prev Cardiol Spring. 2010; 13: 84-90
        • Mora S.
        • Glynn R.J.
        • Hsia J.
        • et al.
        Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials.
        Circ. 2010; 121: 1069-1077
        • Moreno-Arellano S.
        • Delgado-de-Mendoza J.
        • Santi-Cano M.J.
        Sex disparity persists in the prevention of cardiovascular disease in women on statin therapy compared with that in men.
        Nutr Metab Cardiovasc Dis. 2018; https://doi.org/10.1016/j.numecd.2018.03.012
        • Zhang H.
        • Plutzky J.
        • Shubina M.
        • et al.
        Drivers of the sex disparity in statin therapy in patients with coronary artery disease: a cohort study.
        PLoS One. 2016; 11: e0155228
        • Peters S.A.E.
        • Colantonio L.D.
        • Zhao H.
        • et al.
        Sex differences in high-intensity statin use following myocardial infarction in the United States.
        J Am Coll Cardiol. 2018; 71: 1729-1737
        • Moon J.
        • Cohen Sedgh R.
        • Jackevicius C.A.
        Examining the Nocebo Effect of Statins through statin adverse events reported in the food and drug administration adverse event reporting system.
        Circ Cardiovasc Qual Outcomes. 2021; 14: e007480
        • Gulati M.
        • Merz C.N.
        New cholesterol guidelines and primary prevention in women.
        Trends Cardiovasc Med. 2015; 25: 84-94
        • Karalis D.G.
        • Wild R.A.
        • Maki K.C.
        • et al.
        Gender differences in side effects and attitudes regarding statin use in the Understanding Statin Use in America and Gaps in Patient Education (USAGE) study.
        J Clin Lipidol. 2016; 10: 833-841
        • Statins F.D.A.
        Drug safety communication - FDA requests removal of strongest warning against using cholesterol-lowering statins during pregnancy.
        (Available at:)
        • American Diabetes A.
        Standards of medical care in diabetes-2021 abridged for primary care providers.
        Clin Diabetes. 2021; 39: 14-43
        • Marsico F.
        • Paolillo S.
        • Gargiulo P.
        • et al.
        Effects of glucagon-like peptide-1 receptor agonists on major cardiovascular events in patients with Type 2 diabetes mellitus with or without established cardiovascular disease: a meta-analysis of randomized controlled trials.
        Eur Heart J. 2020; 41: 3346-3358
        • McGuire D.K.
        • Shih W.J.
        • Cosentino F.
        • et al.
        Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis.
        JAMA Cardiol. 2021; 6: 148-158
        • Lee M.M.Y.
        • Petrie M.C.
        • McMurray J.J.V.
        • et al.
        How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?: Completed and Ongoing Mechanistic Trials.
        Arterioscler Thromb Vasc Biol. 2020; 40: 506-522
        • Mantsiou C.
        • Karagiannis T.
        • Kakotrichi P.
        • et al.
        Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors as combination therapy for type 2 diabetes: A systematic review and meta-analysis.
        Diabetes Obes Metab. 2020; 22: 1857-1868
        • Reboussin D.M.
        • Allen N.B.
        • Griswold M.E.
        • et al.
        Systematic Review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, detection, evaluation, and management of high blood pressure in adults: a report of the american college of cardiology/American Heart association task force on clinical practice guidelines.
        J Am Coll Cardiol. 2017; https://doi.org/10.1016/j.jacc.2017.11.004
        • McSweeney J.C.
        • Rosenfeld A.G.
        • Abel W.M.
        • et al.
        Preventing and from the American Heart Association.
        Circ. 2016; 133: 1302-1331
        • Kim J.K.
        • Alley D.
        • Seeman T.
        • et al.
        Recent changes in cardiovascular risk factors among women and men.
        J Womens Health (Larchmt). 2006; 15: 734-746
        • Ridker P.M.
        Should aspirin be used for primary prevention in the post-statin era?.
        N Engl J Med. 2018; 379: 1572-1574
        • Lloyd-Jones D.M.
        USPSTF report on aspirin for primary prevention.
        JAMA Cardiol. 2022; 7: 667-669
        • McNeil J.J.
        • Wolfe R.
        • Woods R.L.
        • et al.
        Effect of aspirin on cardiovascular events and bleeding in the healthy elderly.
        N Engl J Med. 2018; https://doi.org/10.1056/NEJMoa1805819
        • Group A.S.C.
        Effects of aspirin for primary prevention in persons with diabetes mellitus.
        N Engl J Med. 2018; https://doi.org/10.1056/NEJMoa1804988
        • Gaziano J.M.
        • Brotons C.
        • Coppolecchia R.
        • et al.
        Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial.
        Lancet. 2018; 392: 1036-1046
        • Rana S.
        • Lemoine E.
        • Granger J.P.
        • et al.
        Preeclampsia: pathophysiology, challenges, and perspectives.
        Circ. 2019; 124: 1094-1112
        • Canto J.G.
        • Rogers W.J.
        • Goldberg R.J.
        • et al.
        Association of age and sex with myocardial infarction symptom presentation and in-hospital mortality.
        JAMA. 2012; 307: 813-822
        • Writing Committee M.
        • Gulati M.
        • Levy P.D.
        • et al.
        2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR guideline for the evaluation and diagnosis of chest pain: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical practice guidelines.
        J Am Coll Cardiol. 2021; 78: e187-e285
        • Bank I.E.M.
        • de Hoog V.C.
        • de Kleijn D.P.V.
        • et al.
        Sex-based differences in the performance of the heart score in patients presenting to the emergency department with acute chest pain.
        J Am Heart Assoc. 2017; 6https://doi.org/10.1161/JAHA.116.005373
        • Sondergaard M.M.
        • Hlatky M.A.
        • Stefanick M.L.
        • et al.
        Association of adverse pregnancy outcomes with risk of atherosclerotic cardiovascular disease in postmenopausal women.
        JAMA Cardiol. 2020; 5: 1390-1398
        • Kwok Y.
        • Kim C.
        • Grady D.
        • et al.
        Meta-analysis of exercise testing to detect coronary artery disease in women.
        Am J Cardiol. 1999; 83: 660-666
        • Gruettner J.
        • Fink C.
        • Walter T.
        • et al.
        Coronary computed tomography and triple rule out CT in patients with acute chest pain and an intermediate cardiac risk profile. Part 1: impact on patient management.
        Eur J Radiol. 2013; 82: 100-105
        • Tonet E.
        • Pompei G.
        • Faragasso E.
        • et al.
        Coronary microvascular dysfunction: PET, CMR and CT assessment.
        J Clin Med. 2021; 10https://doi.org/10.3390/jcm10091848
        • Chapman A.R.
        • Anand A.
        • Boeddinghaus J.
        • et al.
        Comparison of the efficacy and safety of early rule-out pathways for acute myocardial infarction.
        Circ. 2017; 135: 1586-1596
        • Perdoncin E.
        • Duvernoy C.
        Treatment of coronary artery disease in women.
        Methodist Debakey Cardiovasc J. 2017; 13: 201-208
        • Ya'qoub L.
        • Elgendy I.Y.
        • Pepine C.J.
        Syndrome of nonobstructive coronary artery diseases: a comprehensive overview of open artery ischemia.
        Am J Med. 2021; 134: 1321-1329
        • Mukherjee D.
        Myocardial infarction with nonobstructive coronary arteries: a call for individualized treatment.
        J Am Heart Assoc. 2019; 8: e013361
        • Hayes S.N.
        • Tweet M.S.
        • Adlam D.
        • et al.
        Spontaneous coronary artery dissection: JACC State-of-the-art review.
        J Am Coll Cardiol. 2020; 76: 961-984
        • Saw J.
        • Mancini G.B.J.
        • Humphries K.H.
        Contemporary review on spontaneous coronary artery dissection.
        J Am Coll Cardiol. 2016; 68: 297-312
        • Cerrato E.
        • Giacobbe F.
        • Quadri G.
        • et al.
        Antiplatelet therapy in patients with conservatively managed spontaneous coronary artery dissection from the multicentre DISCO registry.
        Eur Heart J. 2021; 42: 3161-3171
        • Chen S.
        • Merchant M.
        • Mahrer K.N.
        • et al.
        Pregnancy-associated spontaneous coronary artery dissection: clinical characteristics, outcomes, and risk during subsequent pregnancy.
        J Invasive Cardiol. 2021; 33: E457-E466
        • Ford T.J.
        • Stanley B.
        • Sidik N.
        • et al.
        1-Year outcomes of angina management guided by invasive coronary function testing (CorMicA).
        JACC Cardiovasc Interv. 2020; 13: 33-45